Andarine (S4) vs ostarine (MK-2866) — what the research says

Chemical reagent intended exclusively for laboratory research (Research Use Only). It is not a medicinal product, dietary supplement, or foodstuff. It is not intended for administration to humans or animals outside a controlled experimental environment.

This material is educational in nature and compares two research reagents from a purely scientific standpoint — the evidence base, models, safety signals. It does not contain, nor is it intended to contain, advice regarding use in humans.

Andarine (S4) and ostarine (MK-2866) are the two non-steroidal SARMs most frequently compared with each other. Both belong to the same family of androgen receptor modulators, yet one significant difference separates them: the maturity of the evidence base. Below we compare them scientifically — without references to physique-related uses and without usage protocols.

Andarine vs ostarine — comparison table

How the evidence base differs

The main axis of difference runs through the maturity of the data. Ostarine (MK-2866) is one of the better-studied compounds of the entire SARM class — its development included studies involving humans, including a phase III stage. This gives ostarine a base against which researchers can relate observations from animal models.

Andarine (S4) sits in a different place on this axis. Its data come predominantly from rodent models. The foundation is formed by the work of Gao et al. (2005) — a model of orchidectomized rats, where observations regarding muscle strength, body composition, and bone were reported — and Kearbey et al. (2007), a model of ovariectomized rats with observations regarding bone and adipose tissue. Advanced phase III clinical trials for S4 are lacking.

A practical conclusion for those conducting research: when comparing these two reagents, ostarine offers a deeper clinical foundation, whereas Andarine (S4) remains a compound of predominantly preclinical and historical value in the development of the class.

This difference has methodological consequences. When a compound has data from studies involving humans, a researcher can relate model observations to reference points described in the clinical literature. In the case of Andarine (S4), such a reference point is considerably narrower — interpretation relies predominantly on extrapolation from rodent models, which increases the uncertainty of the conclusions. This does not render the S4 data worthless; it merely indicates that their weight is different and that every claim requires more cautious formulation.

Selectivity in models

Both compounds were designed around the same idea — selective modulation of the androgen receptor. According to the review by Solomon et al. (2019), the SARM class is intended to stimulate the receptor in a differentiated manner depending on the tissue, differently in muscle and bone than in reproductive tissues.

In the case of ostarine, tissue selectivity was studied both in animal models and under clinical conditions. For Andarine (S4), the selectivity observations come primarily from rodent models. In both cases the same interpretive caution applies: “selectivity in models” is a laboratory observation, not an established, predictable characteristic of action in humans.

Safety signals — what has been reported

The most clearly distinguishing element is the visual profile. For Andarine (S4), the literature and reports have described xanthopsia (yellowish vision) and impaired night vision, linked to affinity for receptors in the retina; the effect was described as reversible. This specific signal is a recognizable hallmark of S4 and does not occur at such intensity in descriptions of ostarine.

The broader safety context of the entire class is organized by Leciejewska et al. (2024), who collect the reported adverse events associated with SARM use, with clear acknowledgment of the limitations of the evidence. The signals described for ostarine in the literature concern mainly areas other than vision. In both cases, the reports should be treated as observations requiring further verification.

Regulatory status and WADA

In regulatory terms, both compounds are in the same position. Neither Andarine (S4) nor ostarine (MK-2866) holds registration as a medicinal product. Both function as research reagents (RUO), intended exclusively for laboratory applications.

In the area of sport, WADA classifies both compounds in category S1 (anabolic agents) — they are substances prohibited in and out of competition. Regulations regarding trade and possession differ between countries.

For those conducting research, this means one common denominator: regardless of differences in the evidence base and the profile of safety signals, both reagents are treated in the same regulatory category. The comparison of Andarine (S4) with ostarine (MK-2866) is therefore a scientific comparison of two laboratory tools, not a comparison of products intended for any use in humans.

Andarine or ostarine — what this means for the researcher

Reducing the comparison to its essence: ostarine (MK-2866) is a compound with a more mature, clinically documented base, whereas Andarine (S4) is an earlier tool with a predominantly preclinical body of work and a characteristic, recognizable signal concerning vision. The choice of reference point in research work depends on the experimental question, not on physique-related comparisons, which have no application in the context of RUO reagents.

FAQ

Andarine or ostarine — which compound is better studied?
Ostarine (MK-2866) has a broader base, including phase III clinical data. Andarine (S4) relies predominantly on preclinical data from rodents.

How does S4 differ from ostarine in terms of safety?
The recognizable signal for S4 is the reported visual disturbances (xanthopsia, impaired night vision, described as reversible). The ostarine profile does not include this at such intensity.

Are both prohibited in sport?
Yes. WADA classifies both in category S1.

Is either of them a medicine or a supplement?
No. Both are research reagents (RUO), not medicinal products or foodstuffs.

See also:
– Andarine profile: Andarine (S4) — research and mechanism
– Class context: guide to SARMs
– Ostarine profile: ostarine (MK-2866) and product page ostarine
– Product page: cardarine
– Product page: Andarine (S4)

Scientific sources

1. Gao W et al. (2005). Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats
2. Kearbey JD et al. (2007). Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats
3. Solomon ZJ et al. (2019). Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications
4. Leciejewska N et al. (2024). Selective androgen receptor modulator use and related adverse events

Bartosz BartczakPhysiotherapist, Personal Trainer

Physiotherapist with 20 years of clinical experience, graduate of Poznan University of Medical Sciences. Founder of One Peptides and lead author of clinical-perspective content.

See Full Bio ›